News

Machine models identified 2% of CBCs as possibly contaminated and flagged 6–9% of inpatient transfusions as potentially unnecessary, explains Maucione.

Despite being considered superior to in-clinic measurements, a substantial number of patients do not follow the HBPM guideline recommendations of 12 readings per week.

This segment of Liver Lineup features an in-depth discussion on hepatocellular carcinoma screening in patients with cirrhosis.

Tim Pflederer, explains how nephrologists can help patients with CKD and ESKD navigate the 2025–2030 Dietary Guidelines, including managing protein, potassium, and phosphorus intake.

This segment of Diabetes Dialogue spotlights the FDA clearance of the MiniMed Go and its collaborative capacity with various other devices.

Adjunctive lumateperone 42 mg improves remission, relieves anxiety and sleep symptoms, and shows sustained safety in patients with treatment-resistant MDD.

This survey highlights several key findings related to patient concerns and caregiver concerns over topical steroids (TCS).

Balentine explains the unique challenges of AI implementation in surgery and reviews his research on current barriers to real-world uptake.

Updated federal guidelines highlight protein intake, with Tim Pflederer emphasizing the importance of individualized nutrition strategies for CKD patients

This segment of the most recent episode of Skin of Color Savvy highlights a conversation between Shawn Kwatra, MD, and Andrew Alexis, MD, MPH.

In a 26-week study, adjunctive seltorexant showed no average weight gain in obese patients with MDD and insomnia unlike quetiapine, according to data presented at ACNP 2026.

This segment of Diabetes Dialogue spotlights the recent announcement of a partnership between Diabeloop and Sequel Med Tech.

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

Interim phase 2 results show NS002 delivered faster absorption and greater early epinephrine exposure than EpiPen, with comparable safety and tolerability.

This segment of Liver Lineup features an in-depth discussion on transplant access with MELD 3.0 and new research about potential disparities it introduces.

This segment of Diabetes Dialogue spotlights the new guidelines’ broad suggestion regarding alcohol, as well as how organizations may interpret it.

These data suggest improvement of care for patients with skin cancer and frail skin through geriatrician use, along with a nurse-led geriatric assessment, may be beneficial.

Lumateperone 42 mg plus antidepressants boosts remission rates and sustains symptom improvement in MDD patients, says Michael E. Thase, MD.

This analysis suggests TYK2 (tyrosine kinase 2) inhibitors may have a dual therapeutic potential to address both skin symptoms of psoriasis and comorbid depressive symptoms.

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

In a 26-week head-to-head study, adjunctive seltorexant led to less weight gain and improved insulin sensitivity trends compared with quetiapine XR in MDD with insomnia.

Sinha describes data supporting the safety and utility of a fasting-mimicking diet in Crohn’s disease and explores what may be next in this line of research.

Post hoc MODIFY data showed no significant eGFR or UACR benefit with lucerastat, though exploratory signals appeared in patients with baseline renal impairment.

Recent research shows a substantial portion of US youths have increased risk of cardiometabolic diseases due to obesity and overweight.

Investigators assessed the post-procedure reparative impact of a combination of vitamin C, E, and ferulic acid treatment in patients in China with atrophic acne scars.

Upton discusses an open-label trial showing a 30 mg per nut very low-dose oral immunotherapy strategy increased multi-nut tolerance and remained safe in children.